Author name: Claritas Rx

In the dynamic terrain of the biopharmaceutical industry, patient services have surfaced as a pivotal differentiator for manufacturers. With an increased emphasis on patient-centric care, pharma manufacturers are rethinking ways to extend beyond mere provision of medication. Today’s patients seek holistic support; they demand comprehensive service programs that guide them through the intricate healthcare labyrinth […]

The field of cell and gene therapy is rapidly transforming today’s treatment landscape for complicated cases like rare diseases. Simon Alfano, Alex Gorham, Alberto Loche, and Pablo Salazar report that biopharmaceutical companies are working diligently to develop new, life-saving products, with over 50 new cell and gene therapies launched in 2024, in an article on McKinsey & Company.

In the complex world of modern healthcare, nestled amid the clinical jargon, the labyrinth of insurance structures, and the pharmaceutical industry, lies a process known as step therapy. Step therapy, often a misunderstood and contentious subject, is a treatment approval protocol that requires patients to first try and fail on one or more preferred, typically

In the intricate web of healthcare, where policy, economics, and patient care converge, rises a contentious practice known as step therapy. Often lauded by insurers for its cost-controlling prowess, step therapy sows seeds of uncertainty for many patients, forcing them to navigate a labyrinth of medications before laying claim to the treatment their doctors initially

The world of specialty pharmaceuticals consistently brings forth groundbreaking therapies, bringing hope to patients suffering from previously incurable conditions. However, their success heavily depends on patient adherence. An in-depth examination of patient journeys indicates a concerning fact – a sizeable number of patients, prescribed these potentially life-saving specialty drugs, discontinue their treatment plans frequently before their

Navigating the patient treatment journey is like solving a complex puzzle for the pharmaceutical industry. At every turn, there are challenges, most notably the phenomenon of patient treatment abandonment. Imagine spending years developing a drug that could potentially save thousands of lives, only to find out that a significant portion of patients who should be

Specialty pharmacists can help patients changing payers or providers, and specialty pharmacy data helps with medication adherence strategies.

Specialty pharmacy distribution is changing as specialty drug treatments become more commonplace. Many biosimilars have entered the rare disease market, directly competing with biologics like Humira that represented breakthroughs in their time. New treatments for a wide range of conditions are also available, including biologics, cell and gene therapies for rare diseases.  Wider adoption of